William French
Cardiovascular Disease · Torrance, CANPI 1962475541
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $126,316 of the $161,480 with a category attached, or 78.2%. Johnson & Johnson accounts for 89.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $127,139 and has fallen 99.5% since, to $633 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 495 payments — averaging $326.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$144K
- Janssen Scientific Affairs, LLC$8K
- Medtronic$3K
- Amgen$2K
- Janssen Research & Development, LLC$1K
- Philips North America LLC$796
- plus $2K from 15 others
Across 390 payments — averaging $5527.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- American Regent$249K
- Esperion Therapeutics, Inc.$117K
- AstraZeneca$115K
- Amgen$98K
- Applied Therapeutics, Inc.$90K
- plus $377K from 12 others
What the payments were for
- Consulting fees$15,87010%
- Speaking & faculty fees$126,31678%
- Travel & lodging$10,3076%
- Food & beverage$8,9876%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 126 | $144,222 |
| Janssen Scientific Affairs, LLC | 7 | $7,672 |
| Medtronic | 232 | $3,106 |
| Amgen | 13 | $2,421 |
| Janssen Research & Development, LLC | 9 | $1,223 |
| Philips North America LLC | 23 | $796 |
| Abbott | 22 | $468 |
| Edwards Lifesciences | 11 | $415 |
| Pfizer | 12 | $205 |
| Shockwave Medical, Inc | 6 | $199 |
| Astellas Pharma US Inc | 6 | $116 |
| Scpharmaceuticals Inc. | 5 | $111 |
| Actelion Pharmaceuticals US, Inc. | 5 | $98 |
| Teleflex LLC | 5 | $91 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $90 |
| Boston Scientific | 3 | $68 |
| Abiomed | 2 | $67 |
| Z-medica, LLC | 1 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| CSL Behring | 1 | $22 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$149,980
- (9148) ICE 3D$200
- Micra$135
- Repatha$125
- IGT Systems Und$107
How this compares
$161,480 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Torrance
- Matthew BudoffTorrance$3.6M
- Ronald OudizTorrance$617K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.